| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
D-Glucose 6-phosphate targets multiple metabolic pathways. It is the starting metabolite for glycolysis and the pentose phosphate pathway. It is a substrate for glycogen synthesis. The compound acts as a metabolic stress signal, particularly when phosphoglucose isomerase (PGI) is inhibited, activating the mTOR pathway and promoting protein synthesis. It also acts as a sarcoendoplasmic reticulum calcium ATPase activity inhibitor. D-Glucose 6-phosphate is transported by SLC37A1 and SLC37A2 phosphate-linked antiporters.
|
|---|---|
| ln Vitro |
In vitro, D-Glucose 6-phosphate is a pivotal metabolite in glycolysis and gluconeogenesis pathways. It is a substrate for glycogen synthesis. The compound acts as a metabolic stress signal that activates the mTOR pathway. It is used in cell-based assays to study glucose metabolism and signaling. D-Glucose 6-phosphate inhibits sarcoendoplasmic reticulum calcium ATPase activity. Its metabolic effects have been characterized in various in vitro systems.
|
| ln Vivo |
In vivo, D-Glucose 6-phosphate is a critical node in cellular energy metabolism. It is generated during glycolysis and glycogenolysis. The compound acts as a metabolic stress signal that activates the mTOR pathway, promoting protein synthesis and participating in cardiac remodeling. It is transported by SLC37A1 and SLC37A2 antiporters. Further in vivo studies have evaluated its role in metabolism and disease.
|
| Enzyme Assay |
D-Glucose 6-phosphate enzyme assays involve measuring its role as a substrate for various metabolic enzymes. Hexokinase or glucokinase activity is assessed by monitoring the phosphorylation of glucose to glucose-6-phosphate. Phosphoglucomutase activity is assessed by monitoring the conversion of glucose-1-phosphate to glucose-6-phosphate. Glycolytic enzyme activities are assessed using glucose-6-phosphate as a substrate. mTOR pathway activation is assessed by measuring phosphorylation of downstream targets. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
D-Glucose 6-phosphate cell-based assays are conducted in various cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with D-Glucose 6-phosphate at varying concentrations. Metabolic flux is assessed by measuring glycolytic intermediates or lactate production. mTOR pathway activation is assessed by Western blot for phosphorylated S6K or 4E-BP1. Calcium ATPase activity is assessed by measuring calcium uptake. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
D-Glucose 6-phosphate in vivo studies are conducted in animal models for metabolic research. Animals are administered D-Glucose 6-phosphate via injection. Metabolic effects are assessed by measuring blood glucose, insulin, and lipid levels. For cardiac remodeling studies, animal models of cardiac hypertrophy or ischemia are used. mTOR pathway activation in tissues is assessed by Western blot. Animals are monitored for clinical signs. Tissues and blood samples are collected for biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
D-Glucose 6-phosphate (MW 260.14 g/mol, C6H13O9P) is a pivotal metabolite in glycolysis and gluconeogenesis. It is also known as Robison ester. The compound is soluble in water. It is stable under recommended storage conditions. D-Glucose 6-phosphate is a substrate for glycogen synthesis. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
D-Glucose 6-phosphate is generally well-tolerated as an endogenous metabolite. The compound is a critical node in cellular energy metabolism. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Aldehydo-D-glucose-6-phosphate is the open-chain form of D-glucose-6-phosphate. It is the conjugate acid of Aldehydo-D-glucose-6-phosphate (2-). D-glucose-6-phosphate has been reported in Streptomyces and Catharanthus roseus, with relevant data available. Aldehydo-D-glucose-6-phosphate is a metabolite found or produced in Saccharomyces cerevisiae. It is an ester formed from glucose and phosphate, produced by mammals and other cells during glucose metabolism. It is a normal component of resting muscle and may be in a continuous equilibrium with fructose-6-phosphate. (Stedman, 26th edition)
D-Glucose 6-phosphate is a pivotal metabolite in glycolysis and gluconeogenesis pathways and a critical node in cellular energy metabolism. It is the starting metabolite for glycolysis and the pentose phosphate pathway and a substrate for glycogen synthesis. The compound acts as a metabolic stress signal activating the mTOR pathway. Its molecular formula is C6H13O9P with a molecular weight of 260.14 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C6H13O9P
|
|---|---|
| Molecular Weight |
260.1358
|
| Exact Mass |
260.03
|
| CAS # |
56-73-5
|
| PubChem CID |
439958
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.97g/cm3
|
| Boiling Point |
564.1ºC at 760 mmHg
|
| Flash Point |
295ºC
|
| Index of Refraction |
1.637
|
| LogP |
-4.5
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
16
|
| Complexity |
263
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
P(=O)(O[H])(O[H])OC([H])([H])[C@]([H])([C@]([H])([C@@]([H])([C@]([H])(C([H])=O)O[H])O[H])O[H])O[H]
|
| InChi Key |
VFRROHXSMXFLSN-SLPGGIOYSA-N
|
| InChi Code |
InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4+,5+,6+/m0/s1
|
| Chemical Name |
[(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8441 mL | 19.2204 mL | 38.4408 mL | |
| 5 mM | 0.7688 mL | 3.8441 mL | 7.6882 mL | |
| 10 mM | 0.3844 mL | 1.9220 mL | 3.8441 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
